A practical Bayesian adaptive design incorporating data from historical controls. (22nd July 2018)

• Record Type: Journal Article
• Authors: Psioda, Matthew A.; Soukup, Mat; Ibrahim, Joseph G.
• Is Part Of: Statistics in medicine. Volume 37:Number 27(2018)
• Page Start: 4054
• Page End: 4070
• Publication Date: 2018-07-22
• Subjects: adaptive design -- Bayesian design -- clinical trial design -- historical control -- power prior; Medical statistics -- Periodicals; Statistique médicale -- Périodiques; Statistiques médicales -- Périodiques; 610.727
• DOI: 10.1002/sim.7897
• Languages: English
• ISSNs: 0277-6715

Abstract

Abstract : In this paper, we develop the fixed‐borrowing adaptive design, a Bayesian adaptive design which facilitates information borrowing from a historical trial using subject‐level control data while assuring a reasonable upper bound on the maximum type I error rate and lower bound on the minimum power. First, one constructs an informative power prior from the historical data to be used for design and analysis of the new trial. At an interim analysis opportunity, one evaluates the degree of prior‐data conflict. If there is too much conflict between the new trial data and the historical control data, the prior information is discarded and the study proceeds to the final analysis opportunity at which time a noninformative prior is used for analysis. Otherwise, the trial is stopped early and the informative power prior is used for analysis. Simulation studies are used to calibrate the early stopping rule. The proposed design methodology seamlessly accommodates covariates in the statistical model, which the authors argue is necessary to justify borrowing information from historical controls. Implementation of the proposed methodology is straightforward for many common data models, including linear regression models, generalized linear regression models, and proportional hazards models. We demonstrate the methodology to design a cardiovascular outcomes trial for a hypothetical new therapy for treatment of type 2 diabetes mellitus and borrow information from the SAVOR trial, one of the earliest cardiovascular outcomes trials designed to assess cardiovascular risk in antidiabetic therapies.